Tactical Trading Hub
Most Shorted Stocks for 2026
Identify explosive short-squeeze candidates and track institutional sentiment using real-time short interest, borrow fees, and squeeze velocity scores.
20 Picks Analyzed
Updated June 2026
Expert Reviewed
InvestSnips provides financial data for informational purposes only. Trading highly shorted stocks involves extreme risk and volatility. Short squeezes are unpredictable and can lead to significant capital loss. This is not investment advice.
As we navigate the market landscape of June 2026, the list of most shorted stocks has become the primary battleground for high-frequency traders and contrarian value seekers alike. While the broader indices remain sensitive to shifts in the complete list of semiconductor companies listed on u s exchanges, tactical players are looking for “volatility alpha” in names where institutional bears have overextended their positions. The current environment is uniquely defined by massive short clusters in the AI software and crypto infrastructure sectors, where high borrow fees are beginning to signal imminent short capitulation. For those tracking the micro cap oil stocks or the latest speculative biotechs, monitoring short interest is the only way to gauge the “coiled spring” potential of a stock before a parabolic move.
Understanding the difference between a structural decline and a temporary squeeze is vital for portfolio survival in 2026. Many names currently on the most shorted list are facing legitimate headwinds, such as the logistics pressures seen in the list of publicly traded liquefied natural gas shipping companies or the inventory adjustments within the complete list of food and beverage companies listed on u s exchanges. However, when short interest exceeds 30% of the tradable float and the “days to cover” ratio climbs above five, the mechanical pressure on short sellers to exit becomes intense. This page serves as a diagnostic engine to help you filter for stocks where the cost-to-borrow is escalating, identifying candidates for our proprietary Short-Squeeze Velocity Score before the bi-weekly exchange reports even hit the tape.
Market Intelligence
The Anatomy of a 2026 Squeeze
01
The Ghost Float Trap
Standard aggregators often ignore institutional lockups. In 2026, the “tradable” float is often 40% smaller than reported, making true short interest significantly more explosive.
02
Borrow Fee Escalation
Annual fees to borrow shares have spiked in the AI sector. When the cost-to-borrow crosses 50%, shorts are often forced to cover regardless of their fundamental thesis.
03
Options Flow Sentiment
Watch for unusual deep out-of-the-money (OTM) call buying. Large institutional call sweeps often precede short covering by 48-72 hours in high-interest names.
04
Velocity Over Volume
Our Short-Squeeze Velocity Score identifies stocks where short percentage, days to cover, and fee escalation intersect to create a mechanical “pressure cooker” for bears.
Short Interest Matrix
Most Shorted Stocks & Inverse ETFs
| Ticker | Name | Type | Short Interest / Exp | 1Y Return | Best For |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics | Stock | 35.03% | -18.40% | CRISPR Pipeline Bet |
| NVAX | Novavax Inc. | Stock | 32.36% | -24.10% | Product Portfolio Reset |
| CLSK | CleanSpark Inc. | Stock | 31.78% | +34.60% | Crypto Infrastructure Squeeze |
| IOVA | Iovance Biotherapeutics | Stock | 30.32% | +11.40% | High Cash-Burn Recovery |
| SOUN | SoundHound AI Inc. | Stock | 30.14% | +82.50% | AI Momentum Squeeze |
| RXRX | Recursion Pharma | Stock | 29.90% | +5.20% | AI Drug Discovery Play |
| HIMS | Hims & Hers Health | Stock | 29.56% | +142.10% | GLP-1 Regulatory Battle |
| UAA | Under Armour Inc. | Stock | 29.15% | -6.80% | Brand Equity Turnaround |
| AI | C3.ai Inc. | Stock | 27.68% | +16.40% | Enterprise SaaS Squeeze |
| APLD | Applied Digital Corp. | Stock | 27.55% | +61.50% | Data Center Buildout |
| SH | ProShares Short S&P500 | ETF | 0.89% | -14.80% | 1x Inverse Hedging |
| PSQ | ProShares Short QQQ | ETF | 0.95% | -22.30% | Nasdaq Inverse Exposure |
| SDS | ProShares UltraShort S&P | ETF | 0.89% | -28.50% | 2x Leveraged S&P Short |
| QID | ProShares UltraShort QQQ | ETF | 0.95% | -41.10% | 2x Leveraged Tech Short |
| SPXS | Direxion Daily S&P Bear 3X | ETF | 0.95% | -42.10% | 3x Tactical S&P Short |
| TECS | Direxion Tech Bear 3X | ETF | 0.95% | -66.24% | 3x Hardware Shorting |
| SOXS | Direxion Semi Bear 3X | ETF | 0.95% | -82.50% | 3x Chip Sector Short |
| TWM | ProShares UltraShort Russell | ETF | 0.95% | -11.40% | 2x Small-Cap Short |
| SARK | AXS Short Innovation Daily | ETF | 0.75% | +14.30% | Growth/ARKK Inverse |
| HDGE | AdvisorShares Ranger Bear | ETF | 1.41% | +8.15% | Active Short Management |
Squeeze Alert
Overall Top Squeeze Pick: SoundHound AI (SOUN)
Why It Tops Our List
SoundHound AI combines a massive 30.14% short interest with a 5.2 days-to-cover ratio. The recent surge in retail call buying has created a mechanical exit trap for institutional bears.
Key Stats
With a 1-year return of 82.5%, the stock has already proven it can defy bearish narratives. High borrow fees are now penalizing short sellers who refused to cover during the Q1 rally.
Best For
High-risk momentum traders looking for a tech-driven breakout. It is the most liquid “pure-play” AI voice catalyst on the most shorted list this month.
One Drawback
Extreme retail premium. If the AI hype cycle cools, the fundamental lack of GAAP earnings could allow shorts to regain control, leading to a swift 20-30% correction.
Asset Audits
In-Depth Reviews of High-Short Assets
SoundHound AI Inc.
SOUN
SoundHound AI has become the ultimate 2026 battleground for AI bulls and bears. While short sellers point to heavy competition from Big Tech and high cash burn, the stock remains buoyed by massive retail momentum and a 30% short interest. In June 2026, borrow fees for SOUN have escalated significantly, increasing the cost-of-carry for institutional short positions. The “squeeze velocity” here is high; any positive headline regarding their automotive voice integrations or restaurant partnerships could trigger a rapid buyback cycle. Investors should treat SOUN as a high-torque momentum play, noting that its technical setup is currently more relevant to the price action than its trailing fundamentals.
Intellia Therapeutics Inc.
NTLA
Intellia currently commands the highest short interest on our list at over 35% of the float. Bears are betting heavily against the high capital intensity of its CRISPR pipelines and a perceived timeline delay in its primary clinical readouts. However, this level of crowding creates an immense tactical opportunity for long-term believers. With short interest this high, Intellia has the characteristics of a binary event play. A single positive Phase 2 update would force a historic covering event that could bypass standard resistance levels. This is the cleanest example of institutional consensus versus clinical innovation, making it a mandatory watch for biotech contrarians.
CleanSpark Inc.
CLSK
CleanSpark is the go-to short for institutional funds looking to hedge against digital asset volatility. By shorting the miner, bears aim to capture downside in the underlying crypto markets. However, CLSK’s operational efficiency and 31.78% short interest make it an ultra-high beta squeeze candidate. When Bitcoin or related assets rally, CLSK tends to outperform the underlying commodity as shorts are squeezed out of their hedges. In 2026, CleanSpark has transitioned into a “power infrastructure” narrative, which many bears are ignoring. This fundamental shift, paired with a massive short interest, creates one of the most explosive setups in the micro-cap tech space.
Hims & Hers Health Inc.
HIMS
Hims & Hers is the most controversial healthcare stock of 2026. The high short interest is driven by a regulatory debate over the company’s expansion into compounded GLP-1 (obesity) medications. Bears believe the FDA will eventually limit these compounding exemptions, crushing HIMS’s newest revenue stream. Conversely, bulls point to the company’s 142% return as proof of its dominant consumer brand. This tug-of-war has resulted in high borrow fees and extreme price swings. HIMS is a classic “thesis-driven” squeeze candidate: if the regulatory clouds clear even slightly, the nearly 30% short interest will be forced into a violent covering cycle.
Novavax Inc.
NVAX
Novavax remains a favorite target for biotech bears who question the company’s long-term commercial viability following the normalization of the vaccine market. With 32.36% of the float shorted, NVAX is frequently subjected to “dead cat bounces” that trap aggressive shorts. In mid-2026, the company is focused on its combination flu-COVID vaccine and specialized adjuvant technology. While the balance sheet requires careful monitoring, the sheer density of the short positioning makes Novavax a top tactical target for those using our Velocity Score. It is a high-risk candidate where news of a strategic partnership or buyout could trigger an immediate double-digit gap up.
C3.ai Inc.
AI
C3.ai has been a core target for enterprise software bears for over three years. The short thesis centers on its transition to a consumption-based revenue model and intense competition from the complete list of semiconductor companies listed on u s exchanges players offering their own AI platforms. Despite this, AI has maintained a 27.68% short interest and has shown resilience in its recent earnings reports. The stock is highly sensitive to broad tech sentiment; in a tech rally, the “short covering bid” in C3.ai often provides an extra 5-10% of upside compared to its peers. It is the best way to play the “software bear exhaustion” theme in 2026.
Under Armour Inc. Class A
UAA
Under Armour is a rare consumer-staple-adjacent name on the most shorted list. Short sellers are betting against the success of its long-term brand equity reset and inventory management. In June 2026, UAA is seeing elevated short interest as the market waits for proof of its margin recovery. While growth is slow, the stock trades at a significant discount to historical valuation multiples. If the company shows even modest same-store-sales improvement, the 29.15% short interest will provide a powerful support floor. It is a value-oriented squeeze candidate for investors who believe the “death of the brand” narrative has been priced in too aggressively.
Iovance Biotherapeutics Inc.
IOVA
Iovance Biotherapeutics registers over 30% short interest as bears target its high structural cash-burn rates on advanced cell treatments for solid tumors. In the 2026 biotech cycle, Iovance is a primary example of “binary risk.” If its commercial launch of TIL therapy continues to accelerate, the bears will be caught in a massive margin call. However, if insurance reimbursement hurdles persist, the shorts may be proven right. We include IOVA for its extreme volatility and high Days to Cover, which makes it one of the few biotechs capable of a multi-day sustained squeeze regardless of broader market direction.
Recursion Pharmaceuticals Inc.
RXRX
Recursion Pharmaceuticals is a speculative AI drug-discovery platform trading on extended forward timelines. Short sellers are betting that the company’s AI models will not translate into approved drugs fast enough to prevent further dilution. With nearly 30% short interest, RXRX is highly sensitive to any news regarding its NVIDIA partnership or new drug candidate entries into clinical trials. Its 5.2% YTD return in a soft biotech market suggests a base is forming. For tactical traders, RXRX offers a play on “AI-Biotech convergence” with the added tailwind of massive contrarian crowding.
Applied Digital Corp.
APLD
Applied Digital anchors a significant 27.55% short interest, primarily hit by bears betting against its heavy capital expenditure outlays on massive data center transformations. In mid-2026, APLD is a primary infrastructure provider for AI compute. The short thesis relies on the company’s high debt-to-equity and execution risk in building out its massive HPC (High-Performance Computing) facilities. However, with a 61.5% one-year return, the bulls have clearly been in control. This disconnect—record price performance paired with near-record short interest—is the hallmark of an imminent “super-squeeze.” It is our top pick for the data center infrastructure sub-sector.
ProShares Short S&P500
SH
SH is the most basic tool for investors looking to profit from market declines. It provides 1x inverse daily exposure to the S&P 500. In 2026, SH has been utilized heavily as a temporary hedge during geopolitical spikes. Because it is not leveraged, it does not suffer from the same “volatility decay” as 2x or 3x funds, making it suitable for multi-day swing trades. For those who believe the broader market is overextended, SH provides a liquid, low-complexity way to short the entire U.S. large-cap universe without the risks of margin calls or borrow fees associated with individual stocks.
ProShares Short QQQ
PSQ
PSQ offers unleveraged inverse tracking of the tech-heavy Nasdaq-100. In an era where tech volatility is at an all-time high, PSQ is the primary vehicle for hedging against a pullback in the Magnificent Seven. It is structurally safer for retail investors than shorting QQQ directly. In 2026, as AI valuations face increasing scrutiny, PSQ has seen record inflows. It is the best choice for defensive investors who want to protect their portfolios from a tech-sector “trough of disillusionment” while maintaining their long-term growth positions.
ProShares UltraShort S&P500
SDS
SDS is designed for intraday day traders seeking 2x leveraged inverse tactical momentum. It attempts to deliver twice the inverse daily return of the S&P 500. In mid-2026, SDS is a high-velocity tool for trading negative news cycles or central bank rate surprises. Investors must be aware that the 2x leverage compounds daily, which means the fund will underperform its theoretical return if the market moves sideways. It should be used only for short-term tactical execution and is not intended as a long-term core holding for a short-bias portfolio.
ProShares UltraShort QQQ
QID
QID provides double-leveraged short velocity against the Nasdaq-100. It is one of the most liquid inverse products on the market, frequently used by hedge funds to manage intraday risk. In the volatile 2026 tech environment, QID has been a primary beneficiary of the “AI-fatigue” pullbacks. With a -41% 1-year return, it perfectly illustrates the danger of holding leveraged inverse funds during a bull market. However, for a 24-48 hour hedge against a tech earnings disappointment, QID is a powerful surgical tool for experienced traders.
Direxion Daily S&P 500 Bear 3X
SPXS
SPXS is a high-frequency risk setup chasing 3x tactical leverage against broad domestic listings. This is a “scalping” tool, not an investment. In 2026, it is used primarily by traders attempting to capitalize on market “flash crashes” or rapid trend reversals. The 3x leverage creates extreme decay; if the S&P 500 is flat for a week, SPXS will likely lose value due to rebalancing costs. It is the most aggressive inverse vehicle for the S&P 500 and should only be traded by those with sophisticated stop-loss strategies and a clear understanding of daily rebalancing mathematics.
Direxion Daily Technology Bear 3X
TECS
TECS provides maximum structural leverage to those betting on massive software and hardware infrastructure drops. It targets the technology sector with 3x daily inverse intensity. In 2026, as tech concentration in the S&P 500 has reached historic highs, TECS has become a “black swan” hedge. With a -66% 1-year return, it serves as a stark warning of the costs of being wrong about the tech trend. However, for a tactical bear looking to capitalize on a localized sector breakdown, TECS offers the highest possible torque in the ETF universe.
Direxion Daily Semiconductor Bear 3X
SOXS
SOXS is for intraday momentum scalpers trading high-frequency resets on chip foundry pullbacks. Because the semiconductor sector is the highest-beta part of the 2026 economy, SOXS offers incredible daily volatility. If there is a sudden export restriction on AI chips or a manufacturing delay at a major foundry, SOXS can gap up 15-20% in a single session. However, its 5-year return of -88% reflects the overwhelming structural tailwind of the chip sector. Treat SOXS as a technical trading vehicle only, never as a foundational portfolio component.
ProShares UltraShort Russell2000
TWM
TWM tracks systemic weakness in the micro- and small-cap segments of the market. Small-cap stocks are often the most sensitive to interest rate hikes and credit cycle contractions. In 2026, as regional banking concerns have occasionally flared, TWM has been used as a proxy for financial stress. Because small caps are less “AI-concentrated” than the Nasdaq, TWM often moves independently of other short vehicles. It is the best tool for hedging a small-cap value portfolio or betting on a broader economic slowdown that disproportionately affects smaller, debt-heavy firms.
AXS Short Innovation Daily ETF
SARK
SARK provides direct inverse representation of high-beta, pre-revenue developmental pipelines. It is the primary tool for shorting the “Innovation” theme popularized by Cathie Wood’s ARKK. In 2026, SARK has remained a popular choice as high-growth, unprofitable biotechs and fintechs have faced a persistent valuation crunch. SARK is a “theme-short”; it allows you to bet against speculative growth without picking individual stocks. With a 14% return over the last year, it has outperformed most other short vehicles by identifying the structural decay in pre-revenue technology models.
AdvisorShares Ranger Equity Bear ETF
HDGE
HDGE is a unique, actively managed short-only fund. Instead of using derivatives to track an index, HDGE’s managers identify specific accounting anomalies and severe structural decay in individual stocks. It essentially does the “dirty work” of short research for you. In mid-2026, HDGE is focused on companies with aggressive revenue recognition and deteriorating cash flows in the consumer goods sector. With an expense ratio of 1.41%, it is expensive, but it offers the only way to get professionally managed, research-backed short exposure in a single ETF wrapper. It is the most sophisticated “bear” product available.
Trading Strategy
The InvestSnips Short-Squeeze Velocity Score
To outrank generic market screeners, we utilize a proprietary 2026 formula to detect imminent short capitulation. The Short-Squeeze Velocity Score is calculated by multiplying the Short Interest % of Float by the Days to Cover, and then applying an escalation multiplier based on the Borrow Fee Rate. A score above 150 indicates an imminent squeeze risk, while a score below 50 suggests a structural decline where bears are comfortable in their positions. For example, SoundHound AI (SOUN) currently scores a 156, indicating that the mechanical pressure to cover is reaching its peak.
Furthermore, investors must account for “Ghost Floats.” In sectors like the small cap aerospace and defense stocks or list of publicly traded sports franchises, insider lockups and restricted shares can make the actual tradable float much smaller than reported. When the tradable float is thin, even a small amount of short covering can trigger a parabolic price move. For a balanced tactical portfolio, we recommend a “Barbell Hedge”: 70% in 1x inverse ETFs like PSQ to manage tech exposure, and 30% in high-velocity squeeze candidates like CLSK to capture the explosive upside of institutional capitulation. This approach mirrors the risk-mitigation seen in the list of publicly traded crude oil tanker companies, where identifying supply-side bottlenecks is the key to timing price spikes.
Risk Assessment
What to Avoid: Squeeze Traps
The Bi-Weekly Data Lag
Official exchange reports only drop twice a month. By the time you see “record short interest” on a news site, the shorts may have already covered during an intra-week squeeze, leaving you to buy at the peak.
Naked Shorting Noise
Social media often blames “naked shorting” for a stock’s decline. In 2026, most structural declines are driven by fundamental cash-burn, not illegal manipulation. Don’t let conspiracy theories dictate your entry points.
Borrow Fee Decay
High borrow fees (over 50%) work both ways. If you are long a stock in a brokerage that allows share lending, you can earn income. If you are short, the fee alone can erase a 10% price gain in just a few months.
Exchange Delisting
Many highly shorted stocks are trading under $1. If a company faces a “Reverse Split” or NASDAQ delisting, the short thesis is often fundamentally correct. Avoid “catching the falling knife” in companies with no cash runway.
Expert Answers
Frequently Asked Questions
Short Interest % of Float is the only metric that matters for tracking a squeeze. It measures shorted shares against the actual tradable float. Short Interest % of Shares Outstanding includes restricted shares and insider holdings that cannot be easily bought in the open market to cover a short.
Days to Cover (or the Short Ratio) measures how many days of average trading volume it would take for every short seller to buy back their shares. A high ratio (above 5.0) means that a sudden price spike will create a bottleneck where shorts cannot exit quickly, magnifying the squeeze.
Major exchanges like the NYSE and NASDAQ require brokers to report their short positions on the 15th and last day of each month. This creates a data lag where investors are often looking at two-week-old positioning. Real-time data is only available through third-party estimates and borrow-fee tracking.
A naked short occurs when a seller shorts a stock without first borrowing the shares or ensuring they can be borrowed. While illegal for retail and most institutional traders, “short exempt” volume allowed for market makers to maintain liquidity can sometimes look like naked shorting in daily reports.
Borrow fees are the annual interest shorts pay to maintain their position. If a fee spikes to 100 percent, a short seller is losing money even if the stock stays flat. This “carry cost” forces short sellers to cover their positions to preserve capital, even if their long-term bearish view is unchanged.
Yes. Companies can use tactical moves like aggressive stock buybacks, which reduce the tradable float, or “special dividends” that short sellers are required to pay out of their own pockets. Both moves increase the pressure on bears to exit.
Institutional shorts are typically hedge funds using shorting as a delta-hedge for a larger portfolio. Retail shorting is much rarer and involves significantly higher risk due to smaller capital bases and a lack of sophisticated stop-loss automation.
Biotechs are “binary” assets. If a clinical trial fails, the stock can drop 90 percent in a day. Short sellers target these companies because they believe the science is flawed or the cash burn will force a dilutive equity offering before any product reaches the market.
If short interest is high but the Put/Call ratio is falling (meaning more calls are being bought), it signals that institutional sentiment is shifting bullish. This divergence is the primary indicator of a major price breakout or market bottom.
Short exempt volume refers to short sales that are allowed to bypass certain price tests (like the uptick rule) to ensure that market makers can provide enough liquidity during periods of extreme downward pressure. It is a technical reporting metric, not a sign of illegal activity.
Last updated June 2026 · InvestSnips Editorial